RenovoRx Statistics
Total Valuation
RenovoRx has a market cap or net worth of $44.59 million. The enterprise value is $30.19 million.
Important Dates
The last earnings date was Thursday, May 15, 2025, after market close.
| Earnings Date | May 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RenovoRx has 36.55 million shares outstanding. The number of shares has increased by 124.44% in one year.
| Current Share Class | 36.55M |
| Shares Outstanding | 36.55M |
| Shares Change (YoY) | +124.44% |
| Shares Change (QoQ) | +25.05% |
| Owned by Insiders (%) | 4.36% |
| Owned by Institutions (%) | 12.01% |
| Float | 29.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 134.12 |
| Forward PS | n/a |
| PB Ratio | 3.39 |
| P/TBV Ratio | 3.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 125.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.07, with a Debt / Equity ratio of 0.01.
| Current Ratio | 9.07 |
| Quick Ratio | 8.54 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -136.13% and return on invested capital (ROIC) is -96.00%.
| Return on Equity (ROE) | -136.13% |
| Return on Assets (ROA) | -69.73% |
| Return on Invested Capital (ROIC) | -96.00% |
| Return on Capital Employed (ROCE) | -81.27% |
| Revenue Per Employee | $24,000 |
| Profits Per Employee | -$1.02M |
| Employee Count | 10 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.95% in the last 52 weeks. The beta is 1.12, so RenovoRx's price volatility has been higher than the market average.
| Beta (5Y) | 1.12 |
| 52-Week Price Change | -10.95% |
| 50-Day Moving Average | 0.99 |
| 200-Day Moving Average | 1.10 |
| Relative Strength Index (RSI) | 70.77 |
| Average Volume (20 Days) | 157,410 |
Short Selling Information
The latest short interest is 250,265, so 0.68% of the outstanding shares have been sold short.
| Short Interest | 250,265 |
| Short Previous Month | 295,074 |
| Short % of Shares Out | 0.68% |
| Short % of Float | 0.86% |
| Short Ratio (days to cover) | 2.18 |
Income Statement
In the last 12 months, RenovoRx had revenue of $240,000 and -$10.16 million in losses. Loss per share was -$0.39.
| Revenue | 240,000 |
| Gross Profit | 146,000 |
| Operating Income | -11.60M |
| Pretax Income | -8.05M |
| Net Income | -10.16M |
| EBITDA | n/a |
| EBIT | -11.60M |
| Loss Per Share | -$0.39 |
Full Income StatementBalance Sheet
The company has $14.58 million in cash and $186,000 in debt, giving a net cash position of $14.40 million or $0.39 per share.
| Cash & Cash Equivalents | 14.58M |
| Total Debt | 186,000 |
| Net Cash | 14.40M |
| Net Cash Per Share | $0.39 |
| Equity (Book Value) | 13.16M |
| Book Value Per Share | 0.36 |
| Working Capital | 14.01M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$10.30 million and capital expenditures -$14,000, giving a free cash flow of -$10.32 million.
| Operating Cash Flow | -10.30M |
| Capital Expenditures | -14,000 |
| Free Cash Flow | -10.32M |
| FCF Per Share | -$0.28 |
Full Cash Flow StatementMargins
| Gross Margin | 60.83% |
| Operating Margin | -4,835.00% |
| Pretax Margin | -4,232.50% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |